Meeting
2019 ASCO Annual Meeting
Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionable molecular alterations and who received molecularly-matched therapies (tx).
Authors
Michael J. Pishvaian
Georgetown University, Washington, DC
Michael J. Pishvaian , Edik Matthew Blais , Patricia DeArbeloa , Jonathan Robert Brody , Lola Rahib , Andrew Eugene Hendifar , Sameh Mikhail , Vincent Chung , Davendra Sohal , Vincent J. Picozzi , Kimberly Mason , Lisa Tibbetts , Emily Lyons , Lynn McCormick Matrisian , Subha Madhavan , Emanuel Petricoin III
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4138)
DOI
10.1200/JCO.2019.37.15_suppl.4138
Abstract #
4138
Poster Bd #
243
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The prognostic value of mutational signatures in pancreatic cancer.
First Author: Nicholas Light
Poster
2016 Gastrointestinal Cancers Symposium
A phase I trial of cabozantinib (XL184) and gemcitabine in advanced pancreatic cancer.
First Author: David Bing Zhen
Poster
2013 ASCO Annual Meeting
Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
First Author: Heike Richly
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Advanced pancreatic cancer outcomes and the impact of COVID-19 pandemic: The experience of an academic cancer center.
First Author: Christian Adams-Carey